Speakers
Alexander Haas
Head Biologics Core Technologies
Roche
Track B Day 2 PM
1:30 pm | Graphical Design, Engineering & In Silico Cloning of Multispecific Antibodies
Aman Singh
Associate Director, Cell Therapy Clinical Pharmacology, Modeling & Bioinformatics
Takeda
Track A Day 2 AM
11:00 am | Translational PK/PD Investigations & Multiscale Mechanism-Based Modeling to Support Development of T Cell Redirecting Antibodies
Ankita Srivastava
Vice President - Protein Sciences & Rational Design
Ichnos Sciences
Track B Day 2 PM
2:00 pm | TREAT 2.0: A Versatile Platform Technology for Development of Multispecific Antibodies
Anthony Stein
Medical Doctor
City of Hope
Day One
Wednesday, September 21 | 2022
3:45 pm | Roundtable Discussion - Clinical Updates from Industry Pioneers in the Multispecific Field
Day Two
Thursday, September 22 | 2022
3:30 pm | Improving Bispecific Antibody Outcome in Acute Myeloid Leukemia
Azra Mujic-Delic
Principal Scientist - Functional Characterization & Bioassays
Genmab
Track B Day 2 AM
11:30 am | Potency Assay Strategy from Early to Late Clinical Development: A Bispecifics Case Study
Brandon Leonard
Principal Scientific Researcher - Antibody Engineering
Genentech
Track B Day 2 PM
2:30 pm | Leveraging Homotypic Antibody Interfaces for Biotherapeutic Engineering
Camille Grandclement
Senior Scientist
Ichnos Sciences
Focus Day Track B - AM
10:30 am | ISB 1442: A First-in-Class CD38 & CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Hematological Malignancies
Chava Kimchi-Sarfaty
Deputy Associate Director - Research Office of Tissue & Advanced Therapies
CBER, FDA
Track B - Day 1 PM
2:15 pm | Exploring the Consequences of Codon Optimization on Therapeutic Sequences
Christopher Mehlin
Chief Scientific Officer & Co-founder
Link Immunotherapeutics
Day One
Wednesday, September 21 | 2022
9:10 am | Panel Discussion – CAR T vs. Multispecifics
Focus Day Track A - PM
2:00 pm | Roundtable Discussion - Understanding Different Formats Behavior to Identify Which One Works Best
Daniel Pereira
Chief Scientific Officer
Invenra
Day Two
Thursday, September 22 | 2022
9:20 am | Uncovering the Therapeutic Potential of a Next Generation Tumor Treg Deplete
David Poon
Vice President – Business Development & Alliance Management
Zymeworks
Track A - Day 1 PM
2:15 pm | Expanding the Therapeutic Window for Immune- Engaging Multi-Specifics Through Conditional Activation & Co-Stimulation
Diego Ellerman
Principal Scientific Researcher
Genentech
Track A - Day 1 PM
1:15 pm | CLEC5a-Directed Bispecific Antibody for Effective Cellular Phagocytosis
Erin Meermeier
Research Associate Scientist - Division of Hematology and Oncology
Mayo Clinic
Focus Day Track A - AM
11:00 am | Evaluating Novel formats & Testing Efficacy in Fully Immunosufficient in vivo Models
Eugene Zhukovsky
Chief Scientific Officer
Ichnos Sciences
Day One
Wednesday, September 21 | 2022
9:10 am | Panel Discussion – CAR T vs. Multispecifics
Ezio Bonvini
Chief Scientific Officer
Macrogenics
Track A Day 2 PM
2:00 pm | Overcoming the Challenges of a First-Generation CD123-Directed Bispecific CD3-Engaging DART Molecule
Harald Kolmar
Department Head Applied Biochemistry
Technical University of Darmstadt
Focus Day Track A - AM
10:30 am | A Productive Relationship for NK Cell Engagement: Multispecific Two-In-One Antibodies
Jeffrey Way
Lecturer - Department of Systems Biology
Harvard Medical School
Track B - Day 1 PM
2:45 pm | Rational Engineering of an Erythropoietin Fusion Protein to Treat Hypoxia”
Jonathan Davis
Vice President - Innovation and Strategy
Invenra
Track B - Day 1 PM
1:45 pm | Correlating Multispecific Structures to their Functions for a Holistic Overview of Product Design
Julia Frei
Principal Scientist
Ichnos Sciences
Track B - Day 1 PM
1:15 pm | ISB 1442, a First-in-Class 2+1 Fc Engineered Biparatopic Bispecific BEAT® 2.0 antibody targeting CD38 and CD47
Kalyan Pande
Associate Principal Scientist – Protein Engineering & Modalities
Merck
Focus Day Track A - PM
1:30 pm | Multimerization of Single-Domain Antibodies Targeting Viral Glycoproteins for Enhanced Potency
Liqin Liu
Senior Director of T Cell Engagers
IGM Biosciences
Focus Day Track B - AM
11:30 am | IGM-2323 - High Avidity IgM-Based CD20xCD3 Bispecific Antibody for Enhanced T Cell Dependent Killing with Minimal Cytokine Release
Martin Siegemund
Senior Scientist
Pieris Pharmaceuticals
Focus Day Track A - AM
11:30 am | Anticalin Proteins as Key Components in Advanced Multispecific Formats
Nimish Gera
Vice President - Biologics Research
Mythic Therapeutics
Focus Day Track B - PM
2:00 pm | Roundtable Discussion - Evaluating Tumor Toxicity for Immune Cell Re-Targeting
Peter Ellmark
Chief Scientific Officer
Alligator Bioscience
Day One
Wednesday, September 21 | 2022
9:10 am | Panel Discussion – CAR T vs. Multispecifics
Day Two
Thursday, September 22 | 2022
4:00 pm | Panel Discussion - Unlocking the Potential of Combinatorial Strategies of Bispecifics in a Clinical Setting
Track A - Day 1 PM
1:45 pm | Kick-Starting Tumor Specific T Cell Cross-Priming Using Neo-X-Prime Bispecific Antibodies Targeting CD40
Pranjali Dalvi
Senior Scientist
Amgen
Track A Day 2 PM
1:30 pm | Decoupling Cytotoxicity with Cytokine Release: Development of Safe CD3 T Cell Engagers for Solid Tumors
Prathap Shastri
Scientific Director, DMPK, Preclinical Sciences and Translational Safety
Johnson & Johnson
Day Two
Thursday, September 22 | 2022
4:00 pm | Panel Discussion - Unlocking the Potential of Combinatorial Strategies of Bispecifics in a Clinical Setting
Track A - Day 1 PM
2:45 pm | Retrospective Look at Translational Considerations & FIH Dosing Approaches for T-cell Redirectors
Rakesh Dixit
President and Head of R&D, Co-Founder
Regio Biosciences
Track A - Day 1 AM
10:45 am | On and Off-Target Toxicities of Bispecific Targeted Biologics: Mitigation Strategies
Shailee Patel
Researcher
Beacon Targeted Therapeutics
Day One
Wednesday, September 21 | 2022
8:30 am | The Landscape of Bi/Multispecifics
Shaun Lippow
Vice President, Drug Discovery & Protein Engineering
Atreca
Track B - Day 1 AM
10:45 am | Engineering Safe & Effective Bispecific Immunotherapies for Solid Tumor Indications
Suzanne Schubbert
Associate Director - Discovery Biology & Pharmacology
Xencor
Focus Day Track B - PM
1:00 pm | LAG3-Targeted IL15/IL15Rα-Fc (LAG3 x IL15) Fusion Protein for Preferential TIL Expansion
Vera Sellers
Associate Director - Molecule Group, Protein & Cell Sciences Discovery & Development Technologies
EMD Serono
Track A - Day 1 AM
11:15 am | Early Developability of Multispecifics
Wadim Matochko
Scientist Antibody Discovery
Amgen
Track B - Day 1 AM
11:15 am | Target Biology & Antibody Attributes Drive Multispecific Format Selection & Engineering
Wei Yan
President & Chief Executive Officer
Sound Biologics
Focus Day Track B - AM
11:00 am | Rationale Design of the Next Generation Bifunctional Checkpoint Inhibitors
Werner Meier
Chief Scientific Officer
Revitope Oncology
Day Two
Thursday, September 22 | 2022
10:00 am | Guided Antibody Tumor Engagers (TwoGATE™), a Sophisticated & Differentiated Approach for T Cell Redirection in Solid Tumors
Yanchen Zhou
Principle Scientist
Amgen
Focus Day Track A - PM
1:00 pm | Understanding the Pre-Existing Reactivity of BsAbs for Mitigation Strategies
Musheng Bao
Senior Director, Discovery Oncology
Harbour Biomed
Track A Day 2 PM
2:30 pm | Generation of Innovative B7H4 x CD3 & B7H4 x 4-1BB Bispecifics for Solid Tumor Therapies
Christel Iffland, PhD.
VP, Antibody Technology
OmniAb, Inc.
Track B - Day 1 AM
11:45 am | Session Reserved for OmniAb
Alexander Schinagl
Chief Technology Officer
OncoOne
Track A Day 2 AM
11:30 am | PreTarg-it®: A modular platform utilizing bispecific antibodies for optimized biodelivery of payloads.
Erin Simonds
Director of Immuno-Oncology
Soteria Biotherapeutics
Pre-Conference Focus Day
1:30 pm | Developing Switchable Bispecific T Cell Engagers to Fight Cancer
John Burke, PhD
Co-Founder, President, and CEO
Applied BioMath
